HK-listed Genscript Biotech unit Probio to raise $150m from Hillhouse Capital

HK-listed Genscript Biotech unit Probio to raise $150m from Hillhouse Capital

Laboratory equipment. Photo: Pixabay

19 August, 2021

CDMO Genscript Biotech Hillhouse Capital Group Probio Cayman

Printed by Unregistered user on Sun, 13 Jul 2025 03:43:52 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

J&J-backed cell therapies developer Legend Biotech files for Nasdaq IPO

Hillhouse backs $150m round in HK-listed MicroPort's heart rhythm management unit

Read more from Greater China

Editor’s Take: The Week That Was—July 7-12

Policy & Regulations

Shanghai to consider policy responses to stablecoins, cryptocurrencies